Crown Bioscience International

Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Screening

Retrieved on: 
Tuesday, November 7, 2023
Data Management, Biotechnology, Alternative Medicine, Technology, FDA, Health, Pharmaceutical, Oncology, Research, Science, Clinical Trials, Carboplatin, AACR, HCI, WES, Organoid, 2D, RNA, Cisplatin, Crown Bioscience International, Timeline, Doctor of Philosophy, KRAS, Senior, Sequence, Paclitaxel, RNA-Seq, NGS, Drug discovery, PDX, ANE, CTG, AR, Automation, Medical imaging, Vitro

This large-scale organoid panel screening platform promises robust, reproducible, and clinically relevant output at record speed, accelerating preclinical oncology drug discovery by empowering researchers and reshaping the landscape of cancer treatment development.

Key Points: 
  • This large-scale organoid panel screening platform promises robust, reproducible, and clinically relevant output at record speed, accelerating preclinical oncology drug discovery by empowering researchers and reshaping the landscape of cancer treatment development.
  • Screening of a large panel of patient-derived organoids is enabled using Crown Bioscience’s unique assay-ready (AR) organoid technology.
  • OrganoidXplore transcends traditional 2D cell culture systems in terms of patient relevance, heralding a significant leap in preclinical drug screening.
  • The Full Panel currently comprises 50 organoid models covering seven cancer indications, which are also available as companion Patient-Derived Xenografts (PDX).

Indivumed Services’ Hamburg Site Receives College of American Pathologists (CAP) Accreditation

Retrieved on: 
Monday, September 11, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Accreditation, College, Crown Bioscience International, Service, CAP, Clinical trial, Multimedia, Doctor of Philosophy, Quality, Gesellschaft mit beschränkter Haftung, Certification, CLIA, Acquisition, Laboratory, Medical device, Nursing

Indivumed Services GmbH, a Crown Bioscience company, announced that its Hamburg site received laboratory accreditation from the College of American Pathologists (CAP).

Key Points: 
  • Indivumed Services GmbH, a Crown Bioscience company, announced that its Hamburg site received laboratory accreditation from the College of American Pathologists (CAP).
  • This distinction places Indivumed Services among the top 10% of laboratories globally, solidifying its commitment to excellence in laboratory services.
  • Overall, Indivumed Services’ CAP accreditation enhances its flexibility and enables the expansion of its services into new markets.
  • Simone Hubo, PhD, Vice President of Quality and Regulatory Affairs at Indivumed Services, stated: “With this accreditation, our customers can rest assured that the samples and analyses provided by Indivumed Services are of industry-leading quality.

Crown Bioscience Enables HanX Biopharmaceutical to Progress HX009 to Clinical Trials

Retrieved on: 
Tuesday, August 22, 2023
Research, FDA, Clinical Trials, Biotechnology, Alternative Medicine, Health, Pharmaceutical, Science, Oncology, Lymphoma, CD47, Partnership, Drug development, Nature, Therapy, Crown Bioscience International, CDX, Raji, Innovation, Toxicity, Doctor of Philosophy, PDX, Organization, Collection, TME, Scientific Reports, Mouse, PD-1, Hanx!, IND, Tumor microenvironment, Palladium, Pharmaceutical industry, Medical imaging

In addition, HX009 exhibited enhanced T-cell activating capability over HX008, an approved and marketed anti-PD-1 monoclonal antibody in China.

Key Points: 
  • In addition, HX009 exhibited enhanced T-cell activating capability over HX008, an approved and marketed anti-PD-1 monoclonal antibody in China.
  • Additionally, custom patient-derived xenograft (PDX) models established by Crown Bioscience, further confirmed the efficacy of CD47 targeting by HX009.
  • These Crown Bioscience studies played an important role in supporting the application of HX009 for the treatment of lymphoma in clinical trials.
  • Henry Li, PhD, Cofounder, Chief Executive Officer and Chief Scientific Officer of HanX, stated: “We are delighted with the exceptional outcomes of our partnership with Crown Bioscience.

FINRA Announces Approval for Corporate Name Change From China Infrastructure Construction Corp. to Cannabis Bioscience International Holdings and Ticker Symbol Change from CHNC to CBIH

Retrieved on: 
Monday, August 21, 2023
FINRA, Financial Industry Regulatory Authority, 205th Infrastructure Construction Engineer Division, Confusion, Crown Bioscience International, Cannabinoid, Research, Pharmaceutical industry

HOUSTON, Texas, Aug. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Cannabis Bioscience International Holdings (the “Company”) a diversified medical and educational company with a particular focus on traditional clinical trials and cannabinoids research, is excited to announce that FINRA (Financial Industry Regulatory Authority, Inc.) has approved the corporate name change from “China Infrastructure Construction Corp.” to “Cannabis Bioscience International Holdings” as well as its ticker symbol change from “CHNC” to “CBIH”.

Key Points: 
  • HOUSTON, Texas, Aug. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Cannabis Bioscience International Holdings (the “Company”) a diversified medical and educational company with a particular focus on traditional clinical trials and cannabinoids research, is excited to announce that FINRA (Financial Industry Regulatory Authority, Inc.) has approved the corporate name change from “China Infrastructure Construction Corp.” to “Cannabis Bioscience International Holdings” as well as its ticker symbol change from “CHNC” to “CBIH”.
  • CBIH’s treasurer Henry Levinski said, “Adopting to a new stock ticker symbol is a reflection of the progress we have made in our strategy of reinventing/rebranding our company since our merger.
  • This further establishes CBIH as a diversified Houston-based company with a clear identity, instead of the two-fold confusion that the former generated in name and ticker symbol.
  • For more information contact us at:

High-Throughput Screening (HTS) Market worth $44.5 billion | MarketsandMarkets

Retrieved on: 
Wednesday, July 5, 2023
Aurora, Bio-Rad Laboratories, Charles River Laboratories, BMG, Corning Inc., Drug development, Therapy, Crown Bioscience International, Czech Republic, Innovative Interstellar Explorer, Product-service system, Agriculture, Disease resistance, High-throughput screening, Rest of the world in sports and games, Merck Group, Research, HTS, Gesellschaft mit beschränkter Haftung, Danaher Corporation, Creative Biolabs, Promega, PerkinElmer, Translational research, Agilent Technologies, Drug discovery, Robotics, Health, Automation, Fine chemical, Pharmaceutical industry, Compact Disc manufacturing, Retail

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=134981950

Key Points: 
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=134981950
    High-Throughput Screening (HTS) Market Advantages:
    Accelerated Drug Discovery: High-throughput screening (HTS) expedites the drug discovery process by quickly screening a large number of compounds against specific targets.
  • Target-specific Screening: HTS enables researchers to target specific molecular pathways or cellular functions, allowing for more focused screening.
  • High-Throughput Screening Market- Report Highlights:
    Refinements in the segments of the global high-throughput screening market:
    Company profiles give a glimpse of the key players in the market with respect to business overviews, financials, product offerings, and recent developments.
  • The biochemical screening and life sciences research segments were newly added to the application chapter of the current edition of the high-throughput screening market report.

High-Throughput Screening (HTS) Market worth $44.5 billion | MarketsandMarkets

Retrieved on: 
Wednesday, July 5, 2023
Aurora, Bio-Rad Laboratories, Charles River Laboratories, BMG, Corning Inc., Drug development, Therapy, Crown Bioscience International, Czech Republic, Innovative Interstellar Explorer, Product-service system, Agriculture, Disease resistance, High-throughput screening, Rest of the world in sports and games, Merck Group, Research, HTS, Gesellschaft mit beschränkter Haftung, Danaher Corporation, Creative Biolabs, Promega, PerkinElmer, Translational research, Agilent Technologies, Drug discovery, Robotics, Health, Automation, Fine chemical, Pharmaceutical industry, Compact Disc manufacturing, Retail

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=134981950

Key Points: 
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=134981950
    High-Throughput Screening (HTS) Market Advantages:
    Accelerated Drug Discovery: High-throughput screening (HTS) expedites the drug discovery process by quickly screening a large number of compounds against specific targets.
  • Target-specific Screening: HTS enables researchers to target specific molecular pathways or cellular functions, allowing for more focused screening.
  • High-Throughput Screening Market- Report Highlights:
    Refinements in the segments of the global high-throughput screening market:
    Company profiles give a glimpse of the key players in the market with respect to business overviews, financials, product offerings, and recent developments.
  • The biochemical screening and life sciences research segments were newly added to the application chapter of the current edition of the high-throughput screening market report.

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023

Retrieved on: 
Thursday, May 11, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Axys, Monoclonal antibody, US Foods, Interest, Crown Bioscience International, AbbVie, Quality of life, PDL, Rights, TKI, Research, NSCLC, Immunotherapy, Lung cancer, Forbes China Celebrity 100, Sale, Bayer Corporation, VEGF, Patient, Investment, EGFR, SMMT, Webcast, Knowledge, Entrepreneurship, PD-1, FDA, Woman, Summit, Collaboration, Phase, Compugen (company), Michelle, Pharmaceutical industry, Security (finance), Cryptocurrency, Management, Pfizer

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the first quarter ended March 31, 2023.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the first quarter ended March 31, 2023.
  • The Collaboration and License Agreement with Akeso closed on January 17, 2023 after going effective following customary waiting periods.
  • In exchange for these rights, Summit committed to an upfront payment of $500 million, which was paid in two installments.
  • Operating cash outflow for the three month ended March 31, 2023 and 2022 was $13.1 million and $19.0 million, respectively.

Crown Bioscience Announces Transaction Closing of Indivumed’s Service Business and Supporting Biobank

Retrieved on: 
Tuesday, April 4, 2023
Biotechnology, Alternative Medicine, FDA, Professional Services, Health, Pharmaceutical, Oncology, Research, Science, Clinical Trials, Finance, Crown Bioscience International, Doctor of Philosophy, Gesellschaft mit beschränkter Haftung, PDX, SOP, Acquisition, CBO, Drug discovery, Immunohistochemistry, Growth, Medical imaging, Pharmaceutical industry, MD

Crown Bioscience , a global contract research organization (CRO) and JSR Life Sciences company, announced today that it has completed its acquisition of the IndivuServ business unit of Indivumed GmbH on March 31, 2023.

Key Points: 
  • Crown Bioscience , a global contract research organization (CRO) and JSR Life Sciences company, announced today that it has completed its acquisition of the IndivuServ business unit of Indivumed GmbH on March 31, 2023.
  • The acquisition of Indivumed Services brings a range of synergistic service platforms to Crown Bioscience, from enhanced immunohistochemistry to spatial transcriptomics, complementing the company’s already established capabilities supporting biomarker discovery.
  • Armin Spura, PhD, CEO of Crown Bioscience, stated: “I am thrilled to welcome the highly experienced Indivumed Services team to Crown Bioscience.
  • Michael Prosser, CBO of Crown Bioscience, added: “The completion of this acquisition demonstrates our commitment to integrating unique capabilities and industry-leading quality into all areas of our business.

Indivumed Evolves into Indivumed Therapeutics to Focus on Data and AI-Driven Advancement of Precision Oncology

Retrieved on: 
Tuesday, April 4, 2023
Database, Drug development, Probability, Crown Bioscience International, Clinical trial, Cancer, Biomarker, Gesellschaft mit beschränkter Haftung, Medicine, Acquisition, Therapy, Pharmaceutical industry

HAMBURG, Germany, April 4, 2023 /PRNewswire/ -- After twenty years as one of the first personalized oncology companies, Indivumed today announced its evolution into Indivumed Therapeutics after the acquisition of Indivumed Services GmbH and its CRO service offerings by Crown Bioscience. Indivumed Therapeutics emerges as an oncology biotech company focused fully on biomarker and therapeutic target discovery and validation, drug development, and clinical trial performance. Indivumed Therapeutics will continue utilizing its global clinical network for biospecimen and clinical data collection to grow its unique multi-omics database using its AI-driven discovery and development platform for novel therapies in oncology.

Key Points: 
  • Indivumed Therapeutics emerges as an oncology biotech company focused fully on biomarker and therapeutic target discovery and validation, drug development, and clinical trial performance.
  • Indivumed Therapeutics will continue utilizing its global clinical network for biospecimen and clinical data collection to grow its unique multi-omics database using its AI-driven discovery and development platform for novel therapies in oncology.
  • "Indivumed's success over the last twenty years has been possible due to our constant focus on highly standardized sample and clinical data collection through a global clinical network.
  • Several patents have already been filed and Indivumed Therapeutics proceeds with the identification process for additional targets and biomarkers.

Indivumed Evolves into Indivumed Therapeutics to Focus on Data and AI-Driven Advancement of Precision Oncology

Retrieved on: 
Tuesday, April 4, 2023
Database, Drug development, Probability, Crown Bioscience International, Clinical trial, Cancer, Biomarker, Gesellschaft mit beschränkter Haftung, Medicine, Acquisition, Therapy, Pharmaceutical industry

HAMBURG, Germany, April 4, 2023 /PRNewswire/ -- After twenty years as one of the first personalized oncology companies, Indivumed today announced its evolution into Indivumed Therapeutics after the acquisition of Indivumed Services GmbH and its CRO service offerings by Crown Bioscience. Indivumed Therapeutics emerges as an oncology biotech company focused fully on biomarker and therapeutic target discovery and validation, drug development, and clinical trial performance. Indivumed Therapeutics will continue utilizing its global clinical network for biospecimen and clinical data collection to grow its unique multi-omics database using its AI-driven discovery and development platform for novel therapies in oncology.

Key Points: 
  • Indivumed Therapeutics emerges as an oncology biotech company focused fully on biomarker and therapeutic target discovery and validation, drug development, and clinical trial performance.
  • Indivumed Therapeutics will continue utilizing its global clinical network for biospecimen and clinical data collection to grow its unique multi-omics database using its AI-driven discovery and development platform for novel therapies in oncology.
  • "Indivumed's success over the last twenty years has been possible due to our constant focus on highly standardized sample and clinical data collection through a global clinical network.
  • Several patents have already been filed and Indivumed Therapeutics proceeds with the identification process for additional targets and biomarkers.